# Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

> **NCT06337084** · PHASE1 · RECRUITING · sponsor: **Monopar Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Bladder Cancer
- Urothelial Carcinoma
- Triple-negative Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Gastric Cancer
- Ovarian Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** MNPR-101-DFO*-89Zr
- **DIAGNOSTIC_TEST:** PET/CT Diagnostic Imaging

## Key facts

- **NCT ID:** NCT06337084
- **Lead sponsor:** Monopar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06337084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06337084, "Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06337084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*